
Annual report 2024
added 12-06-2025
ICON Public Limited Company Net Income 2011-2025 | ICLR
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income ICON Public Limited Company
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 791 M | 612 M | 505 M | 153 M | 332 M | 374 M | 323 M | 281 M | 262 M | 240 M | 172 M | 103 M | 55.4 M | 22.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 791 M | 22.9 M | 302 M |
Quarterly Net Income ICON Public Limited Company
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 112 M | - | -94.3 M | 73.9 M | 97.1 M | - | 91.6 M | 47.8 M | 91.7 M | - | 94.8 M | 91.9 M | 88.3 M | - | 84.5 M | 71.9 M | 78.1 M | - | 74.2 M | 64.8 M | 71.4 M | - | 63.9 M | 61.1 M | 63 M | - | 61.5 M | 58.6 M | 55.9 M | - | 50.3 M | 40.8 M | 36.2 M | - | 27.8 M | 22.5 M | 19 M | - | 17.7 M | 7.96 M | 8.97 M | - | -2.66 M | 13.1 M | 8.35 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 112 M | -94.3 M | 51.6 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Diagnostics research industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-46.9 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
-157 M | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
-797 M | $ 16.36 | -4.05 % | $ 176 M | ||
|
Brainsway Ltd.
BWAY
|
-6.46 M | $ 17.05 | -2.15 % | $ 99.4 M | ||
|
Accelerate Diagnostics
AXDX
|
-14.6 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
-32.1 M | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
-112 M | $ 1.63 | -2.11 % | $ 2.07 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-1.81 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
-23.3 M | - | 0.22 % | $ 16.8 M | ||
|
IQVIA Holdings
IQV
|
1.37 B | $ 221.54 | -1.96 % | $ 40.2 B | ||
|
Castle Biosciences
CSTL
|
18.2 M | $ 38.85 | 2.32 % | $ 1.08 B | ||
|
Global Cord Blood Corporation
CO
|
501 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-53 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-7.13 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-503 M | - | 0.12 % | $ 80.1 M | ||
|
Danaher Corporation
DHR
|
3.9 B | $ 227.08 | -2.28 % | $ 166 B | ||
|
DermTech
DMTK
|
-101 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
197 M | - | - | $ 10.7 B | ||
|
DarioHealth Corp.
DRIO
|
-59.4 M | $ 11.92 | -6.58 % | $ 338 M | ||
|
DexCom
DXCM
|
542 M | $ 66.91 | -2.94 % | $ 25.8 B | ||
|
CareDx, Inc
CDNA
|
-190 M | $ 20.44 | 3.23 % | $ 1.1 B | ||
|
Celcuity
CELC
|
-112 M | $ 105.26 | 4.46 % | $ 4.15 B | ||
|
Enzo Biochem
ENZ
|
-26.1 M | - | -8.98 % | $ 14.8 K | ||
|
Anixa Biosciences
ANIX
|
-12.6 M | $ 3.59 | -25.21 % | $ 115 K | ||
|
Exact Sciences Corporation
EXAS
|
-865 M | $ 101.58 | 0.21 % | $ 18.8 B | ||
|
Co-Diagnostics
CODX
|
-35.3 M | $ 0.34 | -2.96 % | $ 9.98 M | ||
|
Fulgent Genetics
FLGT
|
-42.7 M | $ 27.13 | 0.26 % | $ 820 M | ||
|
Guardant Health
GH
|
-436 M | $ 102.09 | 0.7 % | $ 12.5 B | ||
|
Aspira Women's Health
AWH
|
-27.2 M | - | -6.19 % | $ 10.5 M | ||
|
Koninklijke Philips N.V.
PHG
|
3.32 B | $ 26.6 | -1.52 % | $ 20 B | ||
|
Heska Corporation
HSKA
|
-19.9 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-21.6 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
-1.22 B | $ 134.29 | -1.58 % | $ 21.4 B | ||
|
Charles River Laboratories International
CRL
|
22.2 M | $ 192.57 | -0.96 % | $ 9.89 B | ||
|
Quidel Corporation
QDEL
|
810 M | $ 28.79 | -2.93 % | $ 1.21 B | ||
|
Quotient Limited
QTNT
|
-111 M | - | -11.32 % | $ 1.1 M | ||
|
Quest Diagnostics Incorporated
DGX
|
871 M | $ 182.21 | 0.35 % | $ 20.2 B | ||
|
Biodesix
BDSX
|
-42.9 M | $ 7.94 | -1.0 % | $ 1.03 B | ||
|
Laboratory Corporation of America Holdings
LH
|
746 M | $ 263.51 | -0.46 % | $ 22.1 B | ||
|
IDEXX Laboratories
IDXX
|
888 M | $ 701.07 | -0.91 % | $ 57.8 B | ||
|
Lantheus Holdings
LNTH
|
312 M | $ 66.11 | 4.76 % | $ 4.57 B | ||
|
Agilent Technologies
A
|
1.21 B | $ 139.44 | -2.4 % | $ 42.4 B | ||
|
Biomerica
BMRA
|
-4.97 M | $ 2.55 | -1.07 % | $ 5.86 M | ||
|
Bioventus
BVS
|
-156 M | $ 7.59 | 2.29 % | $ 475 M | ||
|
Check-Cap Ltd.
CHEK
|
-25.1 M | - | - | $ 9.42 M | ||
|
Motus GI Holdings
MOTS
|
-12.9 M | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
863 M | $ 1 395.23 | -1.85 % | $ 29.6 B | ||
|
Myriad Genetics
MYGN
|
-127 M | $ 7.26 | -0.62 % | $ 658 M | ||
|
ENDRA Life Sciences
NDRA
|
-11.5 M | $ 5.47 | -7.6 % | $ 2.94 M |